Stop using Ozempic and seek emergency help immediately if you suspect a severe allergic reaction
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Each time I emailed in I was able to get a response in less than 24 hours
The ongoing global surge in demand for GLP-1 receptor agonists for both licensed and off-label indications continues to limit their availability in the UK
CrossRef The association of multiple metabolic disorders with the severity of fasting blood glucose and hepatic steatosis in a Chinese population with MAFLD: a cross-sectional study of over 3000 participants Xue Qu, Shanshan Jin, Yuqing Shi, Weisong Zhang, Delong Cong, Yangyang Liu Scientific Reports .2025;[Epub] CrossRef Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide Husam Albarmawi, Firas Dabbous, Abdalla Aly, Alia Yousif, Samuel Huse, Maximilian Jara, Andres Quintero, Eric Lawitz Current Medical Research and Opinion .2025
That's the baseline this article is evaluating HumeCare+ against - not a claim that HumeCare+ specifically outperforms other named competitors, since competing programs' clinical protocols were not independently reviewed for this comparison
